Market research
LASA.NSE Lasa Supergenerics Limited
NSE INR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 234M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.64
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE670X01014
- Market cap
- 234M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.64
About
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the manufacturing API bulk drugs products in India and internationally. It offers API products, such as fenbendazole, toldimphos sodium, cyromazine, albendazole, riclabendazole, rafoxanide, ornidazole, 2,6-diiodo-4-nitrophenol, ricobendazole, oxfendazole, closantel base, closantel sodium, nitroxynil, halquinol, and oxyclozanide; and Other API products. The company also provides animal feed ingredients; and reagents for therapeutic use. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Research context
Lasa Supergenerics Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the LASA.NSE discussion.
5 years, 6 months ago
Lasa Supergenerics Limited is currently in a long term uptrend where the price is trading 2.6% above its 200 day moving average.
From a valuation standpoint, the stock is 77.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.1.
Lasa Supergenerics Limited's total revenue rose by 37.4% to $540M since the same quarter in the previous year.
Its net income has increased by 154.4% to $66M since the same quarter in the previous year.
Finally, its free cash flow grew by 111.3% to $242M since the same quarter in the previous year.
Based on the above factors, Lasa Supergenerics Limited gets an overall score of 5/5.